← All trials
NCT06248606
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 6, 2024
- Primary completion
- Mar 31, 2026
- Completion date
- Aug 31, 2028
- First posted
- Feb 8, 2024
- Last posted
- Aug 9, 2024
- Enrollment
- 30
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Hoosier Cancer Research NetworkLead sponsor
- Hoosier Cancer Research NetworkSponsor investigator
- Mirati Therapeutics Inc.Collaborator
- University of VirginiaOfficial
- University of VirginiaCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.